Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202366 · ClinicalTrials.gov registry record
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
A clinical trial, sponsored by CAGE Bio.
- Completed
- Registry status
- 15
- Enrollment target
NCT05202366: Completed study, sponsored by CAGE Bio.
NCT05202366 is a clinical trial that has completed, run by CAGE Bio. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05202366 has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations. Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.
Primary Outcome
Clear 0% nail involvement 1. Almost clear 0%-≤10% nail involvement 2. Mild 10%-\<25% nail involvement 3. Moderate 25%-≤50% nail involvement 4. Severe \>50%-≤75% nail involvement
Interventions
- DRUG CGB-400 Topical Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2024-08-08 |
What the finished NCT05202366 record still lists
NCT05202366 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CGB-400 Topical Gel is the first listed.
NCT05202366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05202366 about?
NCT05202366 is a clinical study titled "An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection". The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 ...
What is the current status of trial NCT05202366?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2022-02-08. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT05202366?
The interventions under investigation include: CGB-400 Topical Gel (DRUG).
Who is sponsoring clinical trial NCT05202366?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI